Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic GnRH agonist that paradoxically suppresses gonadotropin release with chronic use. One of the most commercially important peptide drugs, used in prostate cancer, endometriosis, precocious puberty, and fertility treatments.
The trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Unlike the mixed isomer clomifene (Clomid), enclomiphene is the active anti-estrogenic component without the estrogenic zuclomiphene isomer. Studied as a treatment for secondary hypogonadism that preserves fertility, unlike exogenous testosterone.
Initially stimulates LH and FSH release (flare effect), then downregulates GnRH receptors with continuous exposure, leading to profound suppression of testosterone and estrogen production. This 'chemical castration' effect is therapeutically useful.
Blocks estrogen receptors in the hypothalamus, removing negative feedback on GnRH release. This increases pulsatile GnRH secretion, which stimulates pituitary LH and FSH production, driving endogenous testosterone synthesis while maintaining spermatogenesis.
- Prostate cancer treatment
- Endometriosis
- Uterine fibroids
- Precocious puberty
- Fertility treatments (IVF protocols)
- Secondary hypogonadism treatment
- Testosterone optimization without TRT
- Post-cycle therapy (PCT)
- Fertility preservation in hypogonadal men
- Alternative to clomiphene with fewer estrogenic side effects
- Hot flashes
- Bone density loss with long-term use
- Mood changes and depression
- Initial testosterone flare (prostate cancer)
- Injection site reactions
- Cardiovascular risk with prolonged use
- Headache
- Nausea
- Hot flashes
- Visual disturbances (less common than with clomiphene)
- Not FDA-approved — regulatory status uncertain
FDA-approved as Lupron/Lupron Depot (multiple indications since 1985) and Eligard. One of the highest-revenue peptide drugs historically. Available in 1-month, 3-month, 4-month, and 6-month depot formulations.
Not FDA-approved. Repros Therapeutics (now Allergan) submitted NDA for Androxal but received a Complete Response Letter in 2015. Currently available through compounding pharmacies. Active interest from telehealth clinics as a TRT alternative.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.